Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/transcenta-announces-collaboration-with-agilent-to-develop-a-claudin18-2-companion-diagnostic-to-support-osemitamab-tst001-global-phase-iii-trial-302111036.html
https://www.prnewswire.com/news-releases/transcenta-announces-the-publication-of-preclinical-results-of-177lulu-tst001-radionuclide-antibody-conjugate-as-potential-novel-treatment-option-for-metastatic-gastric-cancer-in-the-european-journal-of-nuclear-medicine-and-mole-302013860.html
https://www.prnewswire.com/news-releases/transcenta-unveils-updated-efficacy-data-from-osemitamab-tst001-plus-capox-as-first-line-treatment-for-ggej-cancer-study-at-esmo-2023-301964563.html
https://www.prnewswire.com/news-releases/fda-grants-transcenta-clearance-to-proceed-with-global-phase-iii-trial-of-osemitamab-tst001-as-first-line-treatment-for-gastricgastroesophageal-cancer-patients-301946033.html
https://www.prnewswire.com/news-releases/transcenta-to-present-three-study-results-at-esmo-2023-301900711.html
https://www.prnewswire.com/news-releases/transcenta-anti-sclerostin-monoclonal-antibody-tst002-blosozumab-received-approval-from-china-cde-to-initiate-phase-ii-clinical-trial-in-patients-with-reduced-bone-mineral-density-301888852.html
https://www.prnewswire.com/news-releases/transcenta-anti-sclerostin-monoclonal-antibody-tst002-blosozumab-received-approval-from-china-cde-to-initiate-phase-ii-clinical-trial-in-patients-with-reduced-bone-mineral-density-301888852.html
https://www.prnewswire.com/news-releases/transcenta-presented-pfs-data-by-cldn18-2-expression-level-from-phase-iii-study-of-osemitamab-tst001-plus-capox-as-the-first-line-treatment-of-advanced-ggej-cancer-at-esmo-gi-annual-congress-2023--301867880.html